多西他赛联合顺铂治疗晚期非小细胞肺癌疗效观察  

Clinical efficacy of combined chemotherapy with docetaxel and low-dose cisplatin for advanced non-small-cell lung cancer

作　　者：肖天林[1] 刘小红[1] 杨超[1] 

机构地区：[1]襄樊市中心医院肿瘤科,湖北襄樊441021

出　　处：《现代肿瘤医学》2009年第9期1703-1705,共3页Journal of Modern Oncology

摘　　要：目的:观察多西他赛联合顺铂治疗非小细胞肺癌的临床疗效及不良反应。方法:对62例非小细胞肺癌患者采用多西他赛联合顺铂方案化疗,多西他赛75mg/m2静脉滴注,d1;顺铂25mg/m2静脉滴注d1-3;3周为一周期,至少治疗2周期。结果:所有患者均完成2个以上周期,有效率46.78%,中位生存期9.6个月。主要不良反应为脱发及骨髓抑制,发生率分别为88.71%及85.48%,其中Ⅲ-Ⅳ度分别为14.52%及8.06%。结论:多西他赛联合顺铂治疗非小细胞肺癌疗效显著,不良反应较小,患者耐受性好。Objective： To evaluate the therapeutic efficacy and toxicity of docetaxel combined with low - dose cis- platin as alternative chemotherapy for advanced non - small - cell lung cancer. Methods： Sixty - two patients with non - small - cell lung cancer received docetaxel combined with cisplatin chemotherapy, docetaxe175mg/m^2 infusion once per week for three weeks ,cisplatin 25mg/m^2 infusion on d1-3 for three weeks, after two consecutive therapy course, each for 3 weeks, evaluation of short term efficacy and side effects were carried out. Results ： All patients received more than 2 courses chemotherapy and the overall response rate was 46.78%, the median survival rate was 9.6 months. The main toxic reactions included alopecia and myelosuppression, the rates were 88.71% and 85.48%, grade Ⅲ- Ⅳreactive rates were 14.52% and 8.06%. Conclusion： Combined chemotherapy of docetaxel and low dose cisplatin for non - small - cell lung cancer is effective and well tolerated.

关 键 词：多西他赛 顺铂 非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]